Zacks.com on MSN17h
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss DrugThe initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill ...
Zacks.com on MSN15h
LLY Falls Around 14% in 3 Months: How to Play the StockEli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...
GlobalData on MSN16h
Viking Therapeutics begins VK2735 Phase II trial for obesity treatmentScheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.
16h
Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...
Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback